Ketogenic Diet Shows Promise for Treatment-Resistant Schizophrenia and Bipolar Disorder

Ruby Urlocker was 17 when the first crisis hit. What followed for the Ottawa-area woman was hospitalization, a schizophrenia diagnosis, and years of antipsychotic medications that her family describe as a different kind of suffering. Her father captured it plainly: episodes of illness were "like a bomb goes off in your house." The medications that were supposed to help, Ruby says, "made her feel numb and blunted. It smothered her creativity." She put it simply: "I never felt happy. I never felt inspired."

Now 27 and living in the Mississauga area, Ruby's story has become a focal point in an emerging conversation about whether a therapeutic ketogenic diet can do for severe psychiatric illness what it has long done for drug-resistant epilepsy: stabilize brain function through metabolic means rather than purely neurotransmitter ones.

What Metabolic Psychiatry Actually Argues

The traditional framework for treating schizophrenia and bipolar disorder targets neurotransmitter chemistry, primarily dopamine regulation. What a growing cohort of researchers now proposes is that for a meaningful subset of patients, metabolic dysfunction upstream of that chemistry may be a primary driver of symptoms. The evidence points to cerebral glucose hypometabolism, oxidative stress, and mitochondrial impairment as features common in both schizophrenia and bipolar disorder, not just downstream complications.

Ketogenic metabolic therapy directly addresses these pathways: ketone bodies enhance mitochondrial function, modulate neurotransmitter systems including GABA, glutamate, and dopamine, and reduce neuroinflammation and oxidative stress. These are the same mechanisms that made the ketogenic diet a proven tool in medication-resistant epilepsy, and investigators are now asking whether the same metabolic shift can produce analogous stabilizing effects in psychiatric illness.

The term "metabolic psychiatry" itself was coined by Dr. Shebani Sethi at Stanford Medicine, who framed the field as one that approaches mental health from an energy conversion perspective, noting that there is increasing evidence psychiatric diseases such as schizophrenia and bipolar disorder stem from metabolic deficits in the brain that affect the excitability of neurons.

The Stanford Pilot Trial: What It Found

In a four-month pilot trial, Sethi's team followed 21 adult participants diagnosed with schizophrenia or bipolar disorder who were taking antipsychotic medications and had a metabolic abnormality such as weight gain, insulin resistance, hypertriglyceridemia, dyslipidemia, or impaired glucose tolerance.

Participants followed a ketogenic diet with approximately 10% of calories from carbohydrates, 30% from protein, and 60% from fat. They were not told to count calories, and the focus was on whole, non-processed foods including protein and non-starchy vegetables, without restricting fat. They also received keto cookbooks and access to a health coach.

Improvements were identified across all psychiatric measures, and the ketogenic nutritional intervention was deemed safe and feasible with a high adherence rate. Critically, the researchers noted a potential dose-response signal: those who adhered most closely showed greater benefit than the semi-adherent group, a finding that has important implications for how any future clinical program would need to be structured.

The trial was published in Psychiatry Research and represents one of the most closely watched pieces of early evidence in the metabolic psychiatry field, though researchers themselves are careful to frame it as a promising signal rather than proof of efficacy.

Why Antipsychotic Medications Create the Problem Keto May Help Solve

One underappreciated dimension of this research is that antipsychotic medications, while effective at regulating brain chemistry, impose a significant metabolic cost. These drugs often cause metabolic side effects such as insulin resistance and obesity, which are distressing enough that many patients stop taking the medications. The adherence problem in serious mental illness is not purely psychiatric; it is metabolic and physical.

Nearly two-thirds of patients initially hospitalized with acute psychosis develop obesity within 20 years of follow-up, and metabolic and other undesirable side effects drive approximately 74% of people to stop their medications. This creates a compounding crisis: the medication suppresses symptoms but degrades physical health, which in turn destabilizes the psychiatric condition.

A ketogenic diet, by lowering insulin and blood glucose and shifting the body away from carbohydrate dependence toward ketone production, may counteract exactly the metabolic harm that antipsychotics impose, while simultaneously providing fuel substrates that the metabolically compromised brain can use more efficiently than glucose.

The Practical Reality of Following Keto Alongside Psychiatric Care

Ruby adopted a strict ketogenic diet during a period of relative stability and under clinical supervision. That sequence matters. This is not a diet you start during acute crisis, and it is not one you manage without medical oversight when you are on psychiatric medications. Antipsychotic drugs affect liver metabolism, blood glucose regulation, and lipid profiles, and layering a high-fat dietary intervention on top of that pharmacology requires monitoring of bloodwork including LDL cholesterol fractions, fasting glucose, HbA1c, and markers of inflammation.

The cardiometabolic trade-offs are real. Some implementations of the ketogenic diet drive increases in LDL cholesterol, particularly LDL particle number, which is a risk factor independent of total cholesterol. Cardiovascular disease is already elevated in people with serious mental illness, making lipid management a genuine clinical concern rather than a footnote.

Early keto-adaptation commonly produces symptoms including headache, insomnia, irritability, excitation, dizziness, and carbohydrate cravings. These are typically mild and resolve within two weeks, and in retrospective analysis the diet was psychiatrically well tolerated by the vast majority of participants. Still, for someone managing active psychotic symptoms or severe mood instability, even a two-week transition period is not trivial without support.

What the Evidence Is and Is Not

It is worth being direct about the state of the field. The clinical literature currently consists of small pilot trials, retrospective analyses, and case reports. There are no large-scale randomized controlled trials yet that definitively establish who benefits, at what level of ketosis, over what duration, or with what safety profile across different antipsychotic regimens. Researchers and clinicians working in this space are explicitly calling for those trials before wider adoption.

Positive results from preclinical studies, case studies, and uncontrolled clinical trials point toward a clinically significant role for ketogenic metabolic therapy in the treatment of serious mental illness and offer hope to millions of individuals worldwide who suffer from those conditions; however, researchers emphasize the need for larger controlled trials.

The mechanistic plausibility is solid. The early human data is encouraging. The gap between those two things and a standard-of-care recommendation is still wide, and crossing it honestly requires the kind of rigorous trial infrastructure that the field is now beginning to build.

Questions Worth Raising with a Clinician

If you or someone in your life is managing treatment-resistant schizophrenia or bipolar disorder, the metabolic psychiatry conversation is worth having with a psychiatrist or metabolic physician. The practical questions to bring include: whether current medications are producing metabolic side effects that a dietary intervention might offset; what baseline bloodwork would need to be established before starting; how LDL and cardiovascular risk would be tracked; and whether any clinical trials in your region are currently enrolling.

For Ruby Urlocker, the shift was meaningful enough to describe as a genuine change in quality of life after years of numbness and diminished creative capacity. That is one patient's account, and it is not a clinical recommendation. But it is exactly the kind of experience that makes the science worth pursuing urgently, and that makes the current research gap feel less like academic caution and more like an obligation to answer faster.